Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-19
2009-02-24
Saeed, Kamal A (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S400000, C548S416000, C548S427000, C548S452000, C548S453000, C548S465000, C548S469000, C548S470000
Reexamination Certificate
active
07495112
ABSTRACT:
The invention encompasses isoindoline compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.
REFERENCES:
patent: 4173652 (1979-11-01), Bruins et al.
patent: 4556673 (1985-12-01), Anderson et al.
patent: 4820828 (1989-04-01), Demers et al.
patent: 5605914 (1997-02-01), Muller
patent: 5658940 (1997-08-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller et al.
patent: 5728844 (1998-03-01), Muller et al.
patent: 5728845 (1998-03-01), Muller et al.
patent: 5736570 (1998-04-01), Muller et al.
patent: 5801195 (1998-09-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5968945 (1999-10-01), Muller et al.
patent: 6011050 (2000-01-01), Muller et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6046221 (2000-04-01), Muller et al.
patent: 6075041 (2000-06-01), Muller
patent: 6667316 (2003-12-01), Man et al.
patent: WO 97/05105 (1997-02-01), None
patent: WO 97/24117 (1997-07-01), None
Morissette, Sherry L. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.” Advanced Drug Delivery Reviews 56(2004): 275-300.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Badger et al.,Drug Discovery Today, 2(10): 427-435 (1997).
Balasubramanian et al.,Annual Reports in Medicinal Chemistry, 33: 151-162 (1998).
Barnes,The European Respiratory Journal, 8(3): 457-462 (1995).
Bazzoni et al.,The New England Journal of Medicine, 334(26): 1717-1725 (1996).
Beutler et al.,Critical Care Medicine, 21(10): S423-S435 (1993).
Buu-Hoi et al.,Journal of Medicinal Chemistry, 13(2): 211-213 (1970).
Burnouf et al.,Annual Reports in Medicinal Chemistry, 33: 91-109 (1998).
Crocker et al.,Drugs of Today, 35(7): 519-535 (1999).
De et al.,Journal of Pharmaceutical Sciences, 64(2): 262-266 (1975).
De Brito et al.,Emerging Drugs: Prospect for Improved Medicines, Chapter 12, pp. 249-268 (1997).
Denis et al.,Investigational New Drugs, 15: 175-185 (1997).
Draetta et al.,Annual Reports in Medicinal Chemistry, 31: 241-248 (1996).
Eger et al.,Arzneim.-Forsch. Drug Research, 40(11): 1073-1075 (1990).
Friderichs et al.,Arzneim.-Forsch. Drug Research, 32(1): 613-620 (1982).
Hart et al.,J. Org. Chem., 48: 289-294 (1983).
He et al.,Journal of Medicinal Chemistry, 41: 4216-4223 (1998).
Hughes et al.,Drug Discovery Today, 2(3): 89-101 (1997).
Kleinman et al.,Journal of Medicinal Chemistry, 41: 266-270 (1998).
Lee et al.,Circulatory Shock, 44: 97-103 (1995).
Levy et al.,Journal of Medicinal Chemistry, 41: 199-223 (1998).
Lombardo,Current Pharmaceutical Design, 1(2): 255-268 (1995).
Marriott,Exp. Opin. Invest. Drugs, 6(8): 1105-1108 (1997).
Miller,Cecil Textbook of Medicine, W. B. Saunders Company, pp. 1071-1077 (1996).
Muller et al.,Bioorganic&Medicinal Chemistry Letters, 8: 2669-2674 (1998).
Muller et al.,Journal of Medicinal Chemistry, 49: 3238-3240 (1996).
Müller et al.,Trends in Pharmacological Sciences, 17(8): 294-298 (1996).
Naafs et al.,International Journal of Dermatology, 24(2): 131-134 (1985).
Natchus et al.,Bioorganic&Medicinal Chemistry Letters, 8: 2077-2080 (1998).
Norman,Exp. Opin. Invest. Drugs, 9(7): 1101-1118 (1999).
Maria et al.,II Farmaco, 50(1′2): 819-827 (1995).
Palfreyman,Drugs of the Future, 20(8): 793-804 (1995).
Salmon et al.,Cecil Textbook of Medicine, W. B. Saunders Company, pp. 1036-1049 (1996).
Shire et al.,Exp. Opin. Ther. Patents, 8(5): 531-544 (1998).
Strieter et al.,Critical Care Medicine, 21(10): S447-S463 (1993).
Steinman et al.,Bioorganic&Medicinal Chemistry Letters, 8: 2087-2092 (1998).
Summers et al.,Annual Reports in Medicinal Chemistry, 33: 131-140 (1998).
Tanaka et al.,Chemical&Pharmaceutical Bulletin, 31(8): 2810-2819 (1983).
Texeira et al.,Trends in Pharmacological Sciences, 18(5): 164-170 (1997).
Torphy,Asthma, Lippincott-Raven Publishers, pp. 1755-1773 (1997).
Torphy et al.,Drug News and Perspectives, 6(4): 203-214 (1993).
Torphy,Respiratory and Critical Care Medicine, 157(2): 351-370 (1998).
Tracey et al.,Annual Review of Cell Biology, 9: 317-343 (1993).
Wojtowicz-Praga et al.,Investigational New Drugs, 15: 61-75 (1997).
Yu et al.,Drugs and Aging, 11(3): 229-244 (1997).
Man Hon-Wah
Muller George W.
Celgene Corporation
Jones Day
Saeed Kamal A
Shterengarts Samantha L
LandOfFree
Isoindoline compounds and methods of making and using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoindoline compounds and methods of making and using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoindoline compounds and methods of making and using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103793